{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:27:51Z","timestamp":1787315271418,"version":"build-2736575974"},"reference-count":92,"publisher":"Bentham Science Publishers Ltd.","issue":"16","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CPB"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Influenza, a highly transmissible respiratory infection caused by influenza viruses A\nand B, poses a persistent threat to global public health due to its high mutation rate, ability to\ndevelop resistance to existing antiviral drugs, and capacity for rapid spread. Current treatment\noptions, including four main classes of antiviral agents\u2014adamantanes, neuraminidase inhibitors,\nRNA-dependent RNA polymerase inhibitors, and polymerase acidic endonuclease inhibitors\u2014\nare limited by the emergence of drug-resistant viral strains, non-specific drug distribution, and\nadverse side effects. Moreover, the effectiveness of traditional vaccines is often compromised by\nantigenic drift and shift, necessitating the development of alternative therapeutic strategies. This\nreview comprehensively explores the potential of novel targeted drug delivery systems to address\nthese limitations and improve influenza management. Nanotechnology-based platforms,\nincluding lipid-based, polymer-based, inorganic, and hybrid nanoparticles, offer enhanced drug\ndelivery through improved bioavailability, targeted action, and controlled release, thus minimizing\nsystemic toxicity and optimizing therapeutic outcomes. Inhalation delivery systems such as\ndry powder inhalers (DPIs), nebulizers, and nanotechnology-based inhalation formulations provide\ndirect delivery of antiviral agents to the respiratory tract, ensuring rapid onset of action with\nreduced systemic side effects. Transdermal delivery methods, including microneedle patches\nand hydrogel-based systems, offer non-invasive alternatives that enhance patient compliance\nand allow for sustained drug release. Furthermore, this review discusses recent innovations, such\nas responsive drug delivery systems and multifunctional nanoparticles capable of simultaneous\ndelivery of multiple therapeutic agents, representing a significant advancement in the fight\nagainst influenza. These novel approaches promise improved targeting and efficacy and enable\npersonalized treatment strategies, enhancing patient outcomes in both seasonal flu and pandemic\nscenarios. Integrating these advanced drug delivery systems into clinical practice could revolutionize\nthe management of influenza, offering a promising pathway toward more effective and\nsafer therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0113892010326373241012061547","type":"journal-article","created":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T07:13:56Z","timestamp":1729667636000},"page":"2554-2565","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Revolutionizing Influenza Treatment: A Deep Dive into Targeted Drug Delivery Systems"],"prefix":"10.2174","volume":"26","author":[{"given":"Sourav","family":"Ghosh","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Technology, School of Medical Sciences, Adamas University, Kolkata, 700126, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sejuti Ray","family":"Chowdhury","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Technology, School of Medical Sciences, Adamas University, Kolkata, 700126, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monosiz","family":"Rahaman","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Technology, School of Medical Sciences, Adamas University, Kolkata, 700126, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biswajit","family":"Basu","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Technology, School of Medical Sciences, Adamas University, Kolkata, 700126, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8242-4541","authenticated-orcid":true,"given":"Bhupendra","family":"Prajapati","sequence":"additional","affiliation":[{"name":"S. K. Patel College of Pharmaceutical Education and Research, Ganpat University, Mehsana, Gujarat, 384012, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"15314","DOI":"10.1038\/srep15314","volume":"5","author":"Shrestha S.","year":"2015","unstructured":"Shrestha S.; Foxman B.; Berus J.; van Panhuis W.G.; Steiner C.; Viboud C.; Rohani P.; The role of influenza in the epidemiology of pneumonia. Sci Rep  2015,5(1),15314","journal-title":"Sci Rep"},{"key":"ref=2","first-page":"39","volume":"7","author":"Moghadami M.","year":"2010","unstructured":"Moghadami M.; Moattari A.; Tabatabaee H.R.; Mirahmadizadeh A.; Rezaianzadeh A.; Hasanzadeh J.; Ebrahimi M.; Zamiri N.; Alborzi A.; Bagheri Lankarani K.; High titers of hemagglutination inhibition antibodies against 2009 H1N1 influenza virus in Southern Iran. Iran J Immunol  2010,7(1),39-48","journal-title":"Iran J Immunol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"e11284","DOI":"10.1371\/journal.pone.0011284","volume":"5","author":"Lee B.Y.","year":"2010","unstructured":"Lee B.Y.; McGlone S.M.; Bailey R.R.; Wiringa A.E.; Zimmer S.M.; Smith K.J.; Zimmerman R.K.; To test or to treat? An analysis of influenza testing and antiviral treatment strategies using economic computer modeling. PLoS One  2010,5(6),e11284","journal-title":"PLoS One"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.antiviral.2013.03.014","volume":"98","author":"Samson M.","year":"2013","unstructured":"Samson M.; Pizzorno A.; Abed Y.; Boivin G.; Influenza virus resistance to neuraminidase inhibitors. Antiviral Res  2013,98(2),174-185","journal-title":"Antiviral Res"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"4962","DOI":"10.1128\/AAC.00793-15","volume":"59","author":"Itoh Y.","year":"2015","unstructured":"Itoh Y.; Shichinohe S.; Nakayama M.; Igarashi M.; Ishii A.; Ishigaki H.; Ishida H.; Kitagawa N.; Sasamura T.; Shiohara M.; Doi M.; Tsuchiya H.; Nakamura S.; Okamatsu M.; Sakoda Y.; Kida H.; Ogasawara K.; Emergence of H7N9 influenza A virus resistant to neuraminidase inhibitors in nonhuman primates. Antimicrob Agents Chemother  2015,59(8),4962-4973","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"4961","DOI":"10.1128\/AAC.00412-11","volume":"55","author":"Kitano M.","year":"2011","unstructured":"Kitano M.; Itoh Y.; Kodama M.; Ishigaki H.; Nakayama M.; Ishida H.; Baba K.; Noda T.; Sato K.; Nihashi Y.; Kanazu T.; Yoshida R.; Torii R.; Sato A.; Ogasawara K.; Efficacy of single intravenous injection of peramivir against influenza B virus infection in ferrets and cynomolgus macaques. Antimicrob Agents Chemother  2011,55(11),4961-4970","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"4795","DOI":"10.1128\/AAC.02817-14","volume":"58","author":"Kitano M.","year":"2014","unstructured":"Kitano M.; Itoh Y.; Ishigaki H.; Nakayama M.; Ishida H.; Pham V.L.; Arikata M.; Shichinohe S.; Tsuchiya H.; Kitagawa N.; Kobayashi M.; Yoshida R.; Sato A.; Le Q.M.; Kawaoka Y.; Ogasawara K.; Efficacy of repeated intravenous administration of peramivir against highly pathogenic avian influenza A (H5N1) virus in cynomolgus macaques. Antimicrob Agents Chemother  2014,58(8),4795-4803","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.antiviral.2008.06.014","volume":"80","author":"Stittelaar K.","year":"2008","unstructured":"Stittelaar K.; Tisdale M.; Vanamerongen G.; Vanlavieren R.; Pistoor F.; Simon J.; Osterhaus A.; Evaluation of intravenous zanamivir against experimental influenza A (H5N1) virus infection in cynomolgus macaques. Antiviral Res  2008,80(2),225-228","journal-title":"Antiviral Res"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1186\/s13054-019-2539-x","volume":"23","author":"Kalil A.C.","year":"2019","unstructured":"Kalil A.C.; Thomas P.G.; Influenza virus-related critical illness: Pathophysiology and epidemiology. Crit Care  2019,23(1),258","journal-title":"Crit Care"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/nature15379","volume":"526","author":"Lakdawala S.S.","year":"2015","unstructured":"Lakdawala S.S.; Jayaraman A.; Halpin R.A.; Lamirande E.W.; Shih A.R.; Stockwell T.B.; Lin X.; Simenauer A.; Hanson C.T.; Vogel L.; Paskel M.; Minai M.; Moore I.; Orandle M.; Das S.R.; Wentworth D.E.; Sasisekharan R.; Subbarao K.; The soft palate is an important site of adaptation for transmissible influenza viruses. Nature  2015,526(7571),122-125","journal-title":"Nature"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/1465-9921-8-73","volume":"8","author":"Nicholls J.M.","year":"2007","unstructured":"Nicholls J.M.; Bourne A.J.; Chen H.; Guan Y.; Peiris J.S.M.; Sialic acid receptor detection in the human respiratory tract: evidence for widespread distribution of potential binding sites for human and avian influenza viruses. Respir Res  2007,8(1),73","journal-title":"Respir Res"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"R30","DOI":"10.1186\/cc12512","volume":"17","author":"Zangrillo A.","year":"2013","unstructured":"Zangrillo A.; Biondi-Zoccai G.; Landoni G.; Frati G.; Patroniti N.; Pesenti A.; Pappalardo F.; Extracorporeal membrane oxygenation (ECMO) in patients with H1N1 influenza infection: A systematic review and meta-analysis including 8 studies and 266 patients receiving ECMO. Crit Care  2013,17(1),R30","journal-title":"Crit Care"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1055\/s-2007-979191","volume":"32","author":"Huber T.","year":"1999","unstructured":"Huber T.; Dietrich D.; Emrich H.; Possible use of amantadine in depression. Pharmacopsychiatry  1999,32(2),47-55","journal-title":"Pharmacopsychiatry"},{"key":"ref=14","first-page":"2288","volume":"58","author":"Tokimatsu I.","year":"2000","unstructured":"Tokimatsu I.; Nasu M.; Anti-influenza A viral drug - Amantadine. Jpn J Clin Med  2000,58(11),2288-2292","journal-title":"Jpn J Clin Med"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"7977","DOI":"10.1021\/jp800171m","volume":"112","author":"Yi M.","year":"2008","unstructured":"Yi M.; Cross T.A.; Zhou H.X.; A secondary gate as a mechanism for inhibition of the M2 proton channel by amantadine. J Phys Chem B  2008,112(27),7977-7979","journal-title":"J Phys Chem B"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"11872","DOI":"10.1021\/bi9014488","volume":"48","author":"Balannik V.","year":"2009","unstructured":"Balannik V.; Wang J.; Ohigashi Y.; Jing X.; Magavern E.; Lamb R.A.; DeGrado W.F.; Pinto L.H.; Design and pharmacological characterization of inhibitors of amantadine-resistant mutants of the M2 ion channel of influenza A virus. Biochemistry  2009,48(50),11872-11882","journal-title":"Biochemistry"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"183","DOI":"10.3390\/microorganisms11010183","volume":"11","author":"Batool S.","year":"2023","unstructured":"Batool S.; Chokkakula S.; Song M.S.; Influenza treatment: Limitations of antiviral therapy and advantages of drug combination therapy. Microorganisms  2023,11(1),183","journal-title":"Microorganisms"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/S0140-6736(99)11433-8","volume":"355","author":"Gubareva L.V.","year":"2000","unstructured":"Gubareva L.V.; Kaiser L.; Hayden F.G.; Influenza virus neuraminidase inhibitors. Lancet  2000,355(9206),827-835","journal-title":"Lancet"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/363418a0","volume":"363","author":"von Itzstein M.","year":"1993","unstructured":"von Itzstein M.; Wu W.Y.; Kok G.B.; Pegg M.S.; Dyason J.C.; Jin B.; Van Phan T.; Smythe M.L.; White H.F.; Oliver S.W.; Colman P.M.; Varghese J.N.; Ryan D.M.; Woods J.M.; Bethell R.C.; Hotham V.J.; Cameron J.M.; Penn C.R.; Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature  1993,363(6428),418-423","journal-title":"Nature"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1093\/cid\/cis352","volume":"55","author":"Yu Y.","year":"2012","unstructured":"Yu Y.; Garg S.; Yu P.A.; Kim H.J.; Patel A.; Merlin T.; Redd S.; Uyeki T.M.; Peramivir use for treatment of hospitalized patients with influenza A(H1N1)pdm09 under emergency use authorization, October 2009-June 2010. Clin Infect Dis  2012,55(1),8-15","journal-title":"Clin Infect Dis"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1586\/eri.11.112","volume":"9","author":"Ikematsu H.","year":"2011","unstructured":"Ikematsu H.; Kawai N.; Laninamivir octanoate: A new long-acting neuraminidase inhibitor for the treatment of influenza. Expert Rev Anti Infect Ther  2011,9(10),851-857","journal-title":"Expert Rev Anti Infect Ther"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1056\/NEJMra050740","volume":"353","author":"Moscona A.","year":"2005","unstructured":"Moscona A.; Neuraminidase inhibitors for influenza. N Engl J Med  2005,353(13),1363-1373","journal-title":"N Engl J Med"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"b5106","DOI":"10.1136\/bmj.b5106","volume":"339","author":"Jefferson T.","year":"2009","unstructured":"Jefferson T.; Jones M.; Doshi P.; Del Mar C.; Neuraminidase inhibitors for preventing and treating influenza in healthy adults: Systematic review and meta-analysis. BMJ  2009,339,b5106","journal-title":"BMJ"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1177\/095632020301400502","volume":"14","author":"Takahashi K.","year":"2003","unstructured":"Takahashi K.; Furuta Y.; Fukuda Y.; Kuno M.; Kamiyama T.; Kozaki K.; Nomura N.; Egawa H.; Minami S.; Shiraki K.; In vitro and in vivo activities of T-705 and oseltamivir against influenza virus. Antivir Chem Chemother  2003,14(5),235-241","journal-title":"Antivir Chem Chemother"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1056\/NEJMoa1716197","volume":"379","author":"Hayden F.G.","year":"2018","unstructured":"Hayden F.G.; Sugaya N.; Hirotsu N.; Lee N.; de Jong M.D.; Hurt A.C.; Ishida T.; Sekino H.; Yamada K.; Portsmouth S.; Kawaguchi K.; Shishido T.; Arai M.; Tsuchiya K.; Uehara T.; Watanabe A.; Baloxavir marboxil for uncomplicated influenza in adults and adolescents. N Engl J Med  2018,379(10),913-923","journal-title":"N Engl J Med"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"S764","DOI":"10.1093\/ofid\/ofy229.2190","volume":"5","author":"Ison M.G.","year":"2018","unstructured":"Ison M.G.; Portsmouth S.; Yoshida Y.; Shishido T.; Hayden F.; Uehara T.; LB16. Phase 3 trial of baloxavir marboxil in high-risk influenza patients (CAPSTONE-2 Study). Open Forum Infect Dis  2018,5(Suppl. 1),S764-S765","journal-title":"Open Forum Infect Dis"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"6461","DOI":"10.1016\/j.vaccine.2012.07.089","volume":"30","author":"Klimov A.I.","year":"2012","unstructured":"Klimov A.I.; Garten R.; Russell C.; Barr I.G.; Besselaar T.G.; Daniels R.; Engelhardt O.G.; Grohmann G.; Itamura S.; Kelso A.; McCauley J.; Odagiri T.; Smith D.; Tashiro M.; Xu X.; Webby R.; Wang D.; Ye Z.; Yuelong S.; Zhang W.; Cox N.; WHO recommendations for the viruses to be used in the 2012 Southern Hemisphere Influenza Vaccine: Epidemiology, antigenic and genetic characteristics of influenza A(H1N1)pdm09, A(H3N2) and B influenza viruses collected from February to September 2011. Vaccine  2012,30(45),6461-6471","journal-title":"Vaccine"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"e4244","DOI":"10.1093\/cid\/ciaa1884","volume":"73","author":"Tenforde M.W.","year":"2021","unstructured":"Tenforde M.W.; Kondor R.J.G.; Chung J.R.; Zimmerman R.K.; Nowalk M.P.; Jackson M.L.; Jackson L.A.; Monto A.S.; Martin E.T.; Belongia E.A.; McLean H.Q.; Gaglani M.; Rao A.; Kim S.S.; Stark T.J.; Barnes J.R.; Wentworth D.E.; Patel M.M.; Flannery B.; Effect of antigenic drift on influenza vaccine effectiveness in the United States \u2014 2019\u20132020. Clin Infect Dis  2021,73(11),e4244-e4250","journal-title":"Clin Infect Dis"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1093\/infdis\/jiy103","volume":"218","author":"Erbelding E.J.","year":"2018","unstructured":"Erbelding E.J.; Post D.J.; Stemmy E.J.; Roberts P.C.; Augustine A.D.; Ferguson S.; Paules C.I.; Graham B.S.; Fauci A.S.; A universal influenza vaccine: The strategic plan for the National Institute of Allergy and Infectious Diseases. J Infect Dis  2018,218(3),347-354","journal-title":"J Infect Dis"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"e0119115","DOI":"10.1371\/journal.pone.0119115","volume":"10","author":"Dong G.","year":"2015","unstructured":"Dong G.; Peng C.; Luo J.; Wang C.; Han L.; Wu B.; Ji G.; He H.; Adamantane-resistant influenza a viruses in the world (1902-2013): Frequency and distribution of M2 gene mutations. PLoS One  2015,10(3),e0119115","journal-title":"PLoS One"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1093\/molbev\/mst204","volume":"31","author":"Garcia V.","year":"2014","unstructured":"Garcia V.; Aris-Brosou S.; Comparative dynamics and distribution of influenza drug resistance acquisition to protein m2 and neuraminidase inhibitors. Mol Biol Evol  2014,31(2),355-363","journal-title":"Mol Biol Evol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1016\/S0140-6736(05)67338-2","volume":"366","author":"Bright R.A.","year":"2005","unstructured":"Bright R.A.; Medina M.; Xu X.; Perez-Oronoz G.; Wallis T.R.; Davis X.M.; Povinelli L.; Cox N.J.; Klimov A.I.; Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: A cause for concern. Lancet  2005,366(9492),1175-1181","journal-title":"Lancet"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1152\/physrev.00008.2006","volume":"86","author":"Page M.J.","year":"2006","unstructured":"Page M.J.; Di Cera E.; Role of Na+ and K+ in enzyme function. Physiol Rev  2006,86(4),1049-1092","journal-title":"Physiol Rev"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"9633","DOI":"10.1038\/s41598-018-27890-4","volume":"8","author":"Omoto S.","year":"2018","unstructured":"Omoto S.; Speranzini V.; Hashimoto T.; Noshi T.; Yamaguchi H.; Kawai M.; Kawaguchi K.; Uehara T.; Shishido T.; Naito A.; Cusack S.; Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil. Sci Rep  2018,8(1),9633","journal-title":"Sci Rep"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"1800666","DOI":"10.2807\/1560-7917.ES.2019.24.3.1800666","volume":"24","author":"Gubareva L.V.","year":"2019","unstructured":"Gubareva L.V.; Mishin V.P.; Patel M.C.; Chesnokov A.; Nguyen H.T.; De La Cruz J.; Spencer S.; Campbell A.P.; Sinner M.; Reid H.; Garten R.; Katz J.M.; Fry A.M.; Barnes J.; Wentworth D.E.; Assessing baloxavir susceptibility of influenza viruses circulating in the United States during the 2016\/17 and 2017\/18 seasons. Euro Surveill  2019,24(3),1800666","journal-title":"Euro Surveill"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"3026","DOI":"10.3389\/fmicb.2018.03026","volume":"9","author":"Takashita E.","year":"2018","unstructured":"Takashita E.; Morita H.; Ogawa R.; Nakamura K.; Fujisaki S.; Shirakura M.; Kuwahara T.; Kishida N.; Watanabe S.; Odagiri T.; Susceptibility of influenza viruses to the novel cap-dependent endonuclease inhibitor baloxavir marboxil. Front Microbiol  2018,9,3026","journal-title":"Front Microbiol"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"1900170","DOI":"10.2807\/1560-7917.ES.2019.24.12.1900170","volume":"24","author":"Takashita E.","year":"2019","unstructured":"Takashita E.; Kawakami C.; Ogawa R.; Morita H.; Fujisaki S.; Shirakura M.; Miura H.; Nakamura K.; Kishida N.; Kuwahara T.; Ota A.; Togashi H.; Saito A.; Mitamura K.; Abe T.; Ichikawa M.; Yamazaki M.; Watanabe S.; Odagiri T.; Influenza A.; H3N2) virus exhibiting reduced susceptibility to baloxavir due to a polymerase acidic subunit I38T substitution detected from a hospitalised child without prior baloxavir treatment, Japan, January 2019. Euro Surveill  2019,24(12),1900170","journal-title":"Euro Surveill"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.coviro.2019.01.006","volume":"35","author":"O\u2019Hanlon R.","year":"2019","unstructured":"O\u2019Hanlon R.; Shaw M.L.; Baloxavir marboxil: The new influenza drug on the market. Curr Opin Virol  2019,35,14-18","journal-title":"Curr Opin Virol"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1177\/0018578719841044","volume":"54","author":"Baker D.E.","year":"2019","unstructured":"Baker D.E.; Baloxavir marboxil. Hosp Pharm  2019,54(3),165-169","journal-title":"Hosp Pharm"},{"key":"ref=40","author":"Flynn S.","year":"2019","unstructured":"Flynn S.;  Modulating docetaxel encapsulation and release from branched vinyl copolymer nanoparticles formed via co-nanoprecipitation Doctor of Philosophy  2019","journal-title":"Modulating docetaxel encapsulation and release from branched vinyl copolymer nanoparticles formed via co-nanoprecipitation Doctor of Philosophy"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1128\/mr.56.1.152-179.1992","volume":"56","author":"Webster R.G.","year":"1992","unstructured":"Webster R.G.; Bean W.J.; Gorman O.T.; Chambers T.M.; Kawaoka Y.; Evolution and ecology of influenza A viruses. Microbiol Rev  1992,56(1),152-179","journal-title":"Microbiol Rev"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/82_2014_396","author":"Yoon S-W.","year":"2014","unstructured":"Yoon S-W.; Webby R.J.; Webster R.G.; Evolution and ecology of influenza A viruses. Influenza Pathogenesis and Control - Volume I  2014,359-375","journal-title":"Influenza Pathogenesis and Control - Volume I"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.3390\/v12091042","volume":"12","author":"Parry R.","year":"2020","unstructured":"Parry R.; Wille M.; Turnbull O.; Geoghegan J.; Holmes E.; Divergent influenza-like viruses of amphibians and fish support an ancient evolutionary association. Viruses  2020,12(9),1042","journal-title":"Viruses"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"407","DOI":"10.3390\/v10080407","volume":"10","author":"Lyons D.M.","year":"2018","unstructured":"Lyons D.M.; Lauring A.S.; Mutation and epistasis in influenza virus evolution. Viruses  2018,10(8),407","journal-title":"Viruses"},{"key":"ref=45","first-page":"255","author":"Jiang D.","year":"2021","unstructured":"Jiang D.; Could the Environment Affect the Mutation of H1N1 Influenza Virus? Advances in Clinical Immunology, Medical Microbiology, COVID-19, and Big Data  2021,255-267","journal-title":"Advances in Clinical Immunology, Medical Microbiology, COVID-19, and Big Data"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.apsb.2015.07.006","volume":"5","author":"Shen Z.","year":"2015","unstructured":"Shen Z.; Lou K.; Wang W.; New small-molecule drug design strategies for fighting resistant influenza A. Acta Pharm Sin B  2015,5(5),419-430","journal-title":"Acta Pharm Sin B"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.coviro.2016.05.004","volume":"18","author":"Yen H.L.","year":"2016","unstructured":"Yen H.L.; Current and novel antiviral strategies for influenza infection. Curr Opin Virol  2016,18,126-134","journal-title":"Curr Opin Virol"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"S1669","DOI":"10.1093\/clinids\/11.Supplement_7.S1669","volume":"11","author":"Scheld W.M.","year":"1989","unstructured":"Scheld W.M.; Drug delivery to the central nervous system: General principles and relevance to therapy for infections of the central nervous system. Clin Infect Dis  1989,11(Suppl. 7),S1669-S1690","journal-title":"Clin Infect Dis"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"104718","DOI":"10.1016\/j.antiviral.2020.104718","volume":"175","author":"Takashita E.","year":"2020","unstructured":"Takashita E.; Daniels R.S.; Fujisaki S.; Gregory V.; Gubareva L.V.; Huang W.; Hurt A.C.; Lackenby A.; Nguyen H.T.; Pereyaslov D.; Roe M.; Samaan M.; Subbarao K.; Tse H.; Wang D.; Yen H.L.; Zhang W.; Meijer A.; Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2017\u20132018. Antiviral Res  2020,175,104718","journal-title":"Antiviral Res"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1208\/s12249-020-01908-5","volume":"22","author":"Pradhan D.","year":"2021","unstructured":"Pradhan D.; Biswasroy P.; Goyal A.; Ghosh G.; Rath G.; Recent advancement in nanotechnology-based drug delivery system against viral infections. AAPS PharmSciTech  2021,22(1),47","journal-title":"AAPS PharmSciTech"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"557","DOI":"10.4155\/tde-2017-0008","volume":"8","author":"Aderibigbe B.A.","year":"2017","unstructured":"Aderibigbe B.A.; Polymeric therapeutic delivery systems for the treatment of infectious diseases. Ther Deliv  2017,8(7),557-576","journal-title":"Ther Deliv"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1177\/2049936117713593","volume":"4","author":"Singh L.","year":"2017","unstructured":"Singh L.; Kruger H.G.; Maguire G.E.M.; Govender T.; Parboosing R.; The role of nanotechnology in the treatment of viral infections. Ther Adv Infect Dis  2017,4(4),105-131","journal-title":"Ther Adv Infect Dis"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3390\/pharmaceutics13010031","volume":"13","author":"Chaurasiya B.","year":"2020","unstructured":"Chaurasiya B.; Zhao Y.Y.; Dry powder for pulmonary delivery: A comprehensive review. Pharmaceutics  2020,13(1),31","journal-title":"Pharmaceutics"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"3270","DOI":"10.1021\/acs.molpharmaceut.0c00390","volume":"17","author":"Zhu C.","year":"2020","unstructured":"Zhu C.; Chen J.; Yu S.; Que C.; Taylor L.S.; Tan W.; Wu C.; Zhou Q.T.; Inhalable nanocomposite microparticles with enhanced dissolution and superior aerosol performance. Mol Pharm  2020,17(9),3270-3280","journal-title":"Mol Pharm"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1007\/s10853-020-05361-4","volume":"56","author":"Pham D.T.","year":"2021","unstructured":"Pham D.T.; Chokamonsirikun A.; Phattaravorakarn V.; Tiyaboonchai W.; Polymeric micelles for pulmonary drug delivery: A comprehensive review. J Mater Sci  2021,56(3),2016-2036","journal-title":"J Mater Sci"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1201\/9780429399039-2","author":"Peer D.","year":"2020","unstructured":"Peer D.; Karp J.M.; Hong S.; Farokhzad O.C.; Margalit R.; Langer R.; Nanocarriers as an emerging platform for cancer therapy. Nano-Enabled Medical Applications  2020,61-91","journal-title":"Nano-Enabled Medical Applications"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/nmat3776","volume":"12","author":"Mura S.","year":"2013","unstructured":"Mura S.; Nicolas J.; Couvreur P.; Stimuli-responsive nanocarriers for drug delivery. Nat Mater  2013,12(11),991-1003","journal-title":"Nat Mater"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.colsurfb.2009.09.010","volume":"75","author":"Shakeel F.","year":"2010","unstructured":"Shakeel F.; Ramadan W.; Transdermal delivery of anticancer drug caffeine from water-in-oil nanoemulsions. Colloids Surf B Biointerfaces  2010,75(1),356-362","journal-title":"Colloids Surf B Biointerfaces"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1007\/s11095-016-1958-5","volume":"33","author":"Bobo D.","year":"2016","unstructured":"Bobo D.; Robinson K.J.; Islam J.; Thurecht K.J.; Corrie S.R.; Nanoparticle-based medicines: A review of FDA-approved materials and clinical trials to date. Pharm Res  2016,33(10),2373-2387","journal-title":"Pharm Res"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"50","DOI":"10.54660\/.IJMRGE.2023.4.5.50-55","volume":"4","author":"Hoque M.","year":"2023","unstructured":"Hoque M.; Hossain M.S.; Akram T.; Das S.R.; Advancing healthcare: Exploring recent innovations in drug delivery systems. Int J Multidiscip Res Growth Eval  2023,4(5),50-55","journal-title":"Int J Multidiscip Res Growth Eval"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"100134","DOI":"10.1016\/j.medidd.2022.100134","volume":"15","author":"Sultana A.","year":"2022","unstructured":"Sultana A.; Zare M.; Thomas V.; Kumar T.S.S.; Ramakrishna S.; Nano-based drug delivery systems: Conventional drug delivery routes, recent developments and future prospects. Med Drug Discov  2022,15,100134","journal-title":"Med Drug Discov"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.3390\/nano10071403","volume":"10","author":"Begines B.","year":"2020","unstructured":"Begines B.; Ortiz T.; P\u00e9rez-Aranda M.; Mart\u00ednez G.; Merinero M.; Arg\u00fcelles-Arias F.; Alcudia A.; Polymeric nanoparticles for drug delivery: Recent developments and future prospects. Nanomaterials (Basel)  2020,10(7),1403","journal-title":"Nanomaterials (Basel)"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.addr.2020.07.006","volume":"157","author":"Hickey A.J.","year":"2020","unstructured":"Hickey A.J.; Emerging trends in inhaled drug delivery. Adv Drug Deliv Rev  2020,157,63-70","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=64","first-page":"427","author":"da Rocha S.R.","year":"2019","unstructured":"da Rocha S.R.; Bharatwaj B.; Heyder R.S.; Yang L.; Pressurized metered-dose inhalers. Pharmaceutical Inhalation Aerosol Technology  2019,427-453","journal-title":"Pharmaceutical Inhalation Aerosol Technology"},{"key":"ref=65","first-page":"65","volume":"2","author":"Torchilin V.P.","year":"1985","unstructured":"Torchilin V.P.; Liposomes as targetable drug carriers. Crit Rev Ther Drug Carrier Syst  1985,2(1),65-115","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"1801526","DOI":"10.1002\/advs.201801526","volume":"6","author":"Cai W.","year":"2019","unstructured":"Cai W.; Wang J.; Chu C.; Chen W.; Wu C.; Liu G.; Metal\u2013organic framework\u2010based stimuli\u2010responsive systems for drug delivery. Adv Sci (Weinh)  2019,6(1),1801526","journal-title":"Adv Sci (Weinh)"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"110254","DOI":"10.1016\/j.mehy.2020.110254","volume":"144","author":"Mehta M.","year":"2020","unstructured":"Mehta M.; Prasher P.; Sharma M.; Shastri M.D.; Khurana N.; Vyas M.; Dureja H.; Gupta G.; Anand K.; Satija S.; Chellappan D.K.; Dua K.; Advanced drug delivery systems can assist in targeting coronavirus disease (COVID-19): A hypothesis. Med Hypotheses  2020,144,110254","journal-title":"Med Hypotheses"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1477-3155-3-1","volume":"3","author":"Kouassi G.K.","year":"2005","unstructured":"Kouassi G.K.; Irudayaraj J.; McCarty G.; Interaction of silver nanoparticles with HIV-1. J Nanobiotechnology  2005,3(1),1-10","journal-title":"J Nanobiotechnology"},{"key":"ref=69","first-page":"47","author":"Parveen S.","year":"2017","unstructured":"Parveen S.; Misra R.; Sahoo S.K.; Nanoparticles: A boon to drug delivery, therapeutics, diagnostics and imaging Nanomedicine in Cancer  2017,47-98","journal-title":"Nanomedicine in Cancer"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1039\/b816475b","volume":"38","author":"He Q.","year":"2009","unstructured":"He Q.; Cui Y.; Li J.; Molecular assembly and application of biomimetic microcapsules. Chem Soc Rev  2009,38(8),2292-2303","journal-title":"Chem Soc Rev"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s41598-017-00200-0","volume":"7","author":"Timin A.S.","year":"2017","unstructured":"Timin A.S.; Muslimov A.R.; Petrova A.V.; Lepik K.V.; Okilova M.V.; Vasin A.V.; Afanasyev B.V.; Sukhorukov G.B.; Hybrid inorganic-organic capsules for efficient intracellular delivery of novel siRNAs against influenza A (H1N1) virus infection. Sci Rep  2017,7(1),102","journal-title":"Sci Rep"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"9651","DOI":"10.1021\/acsami.6b01921","volume":"8","author":"Gao H.","year":"2016","unstructured":"Gao H.; Goriacheva O.A.; Tarakina N.V.; Sukhorukov G.B.; Intracellularly biodegradable polyelectrolyte\/silica composite microcapsules as carriers for small molecules. ACS Appl Mater Interfaces  2016,8(15),9651-9661","journal-title":"ACS Appl Mater Interfaces"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.3390\/molecules23092205","volume":"23","author":"Mhlwatika Z.","year":"2018","unstructured":"Mhlwatika Z.; Aderibigbe B.A.; Application of dendrimers for the treatment of infectious diseases. Molecules  2018,23(9),2205","journal-title":"Molecules"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.3389\/fimmu.2018.02224","volume":"9","author":"Pati R.","year":"2018","unstructured":"Pati R.; Shevtsov M.; Sonawane A.; Nanoparticle vaccines against infectious diseases. Front Immunol  2018,9,2224","journal-title":"Front Immunol"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"4580","DOI":"10.2174\/1381612826666200610111013","volume":"26","author":"Ng P.Q.","year":"2020","unstructured":"Ng P.Q.; Ling L.S.C.; Chellian J.; Madheswaran T.; Panneerselvam J.; Kunnath A.P.; Gupta G.; Satija S.; Mehta M.; Hansbro P.M.; Collet T.; Dua K.; Chellappan D.K.; Applications of nanocarriers as drug delivery vehicles for active phytoconstituents. Curr Pharm Des  2020,26(36),4580-4590","journal-title":"Curr Pharm Des"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"e13292","DOI":"10.1111\/dth.13292","volume":"33","author":"Pandey P.","year":"2020","unstructured":"Pandey P.; Satija S.; Wadhwa R.; Mehta M.; Purohit D.; Gupta G.; Prasher P.; Chellappan D.K.; Awasthi R.; Dureja H.; Dua K.; Emerging trends in nanomedicine for topical delivery in skin disorders: Current and translational approaches. Dermatol Ther  2020,33(3),e13292","journal-title":"Dermatol Ther"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.cbi.2019.05.028","volume":"308","author":"Mehta M.","year":"2019","unstructured":"Mehta M.; Deeksha; Tewari, D.; Gupta, G.; Awasthi, R.; Singh, H.; Pandey, P.; Chellappan, D.K.; Wadhwa, R.; Collet, T.; Hansbro, P.M.; Kumar, S.R.; Thangavelu, L.; Negi, P.; Dua, K.; Satija, S. Oligonucleotide therapy: An emerging focus area for drug delivery in chronic inflammatory respiratory diseases. Chem Biol Interact  2019,308,206-215","journal-title":"Chem Biol Interact"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"108720","DOI":"10.1016\/j.cbi.2019.06.033","volume":"309","author":"Sharma P.","year":"2019","unstructured":"Sharma P.; Mehta M.; Dhanjal D.S.; Kaur S.; Gupta G.; Singh H.; Thangavelu L.; Rajeshkumar S.; Tambuwala M.; Bakshi H.A.; Chellappan D.K.; Dua K.; Satija S.; Emerging trends in the novel drug delivery approaches for the treatment of lung cancer. Chem Biol Interact  2019,309,108720","journal-title":"Chem Biol Interact"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.cbi.2019.02.021","volume":"304","author":"Mehta M.","year":"2019","unstructured":"Mehta M.; Deeksha; Sharma, N.; Vyas, M.; Khurana, N.; Maurya, P.K.; Singh, H.; Andreoli de Jesus, T.P.; Dureja, H.; Chellappan, D.K.; Gupta, G.; Wadhwa, R.; Collet, T.; Hansbro, P.M.; Dua, K.; Satija, S. Interactions with the macrophages: An emerging targeted approach using novel drug delivery systems in respiratory diseases. Chem Biol Interact  2019,304,10-19","journal-title":"Chem Biol Interact"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"31","DOI":"10.4155\/tde-2021-0070","volume":"13","author":"Khairnar S.V.","year":"2022","unstructured":"Khairnar S.V.; Jain D.D.; Tambe S.M.; Chavan Y.R.; Amin P.D.; Nebulizer systems: A new frontier for therapeutics and targeted delivery. Ther Deliv  2022,13(1),31-49","journal-title":"Ther Deliv"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.4187\/respcare.03592","volume":"60","author":"Alhamad B.R.","year":"2015","unstructured":"Alhamad B.R.; Fink J.B.; Harwood R.J.; Sheard M.M.; Ari A.; Effect of aerosol devices and administration techniques on drug delivery in a simulated spontaneously breathing pediatric tracheostomy model. Respir Care  2015,60(7),1026-1032","journal-title":"Respir Care"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"277","DOI":"10.4155\/tde.14.3","volume":"5","author":"Weers J.","year":"2014","unstructured":"Weers J.; Tarara T.; The PulmoSphere\u2122 platform for pulmonary drug delivery. Ther Deliv  2014,5(3),277-295","journal-title":"Ther Deliv"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"113","DOI":"10.2147\/COPD.S274846","volume":"16","author":"Usmani O.S.","year":"2021","unstructured":"Usmani O.S.; Roche N.; Jenkins M.; Stjepanovic N.; Mack P.; De Backer W.; Consistent pulmonary drug delivery with whole lung deposition using the aerosphere inhaler: A review of the evidence. Int J Chron Obstruct Pulmon Dis  2021,16,113-124","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/B978-0-12-814531-9.00008-7","author":"Zhang F.","year":"2019","unstructured":"Zhang F.; Santos H.A.; Chapter 8 - Photosensitive materials for constructing on-demanded drug-release systems. Photoactive Inorganic Nanoparticles  2019,193-210","journal-title":"Photoactive Inorganic Nanoparticles"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1080\/10717544.2021.1938756","volume":"28","author":"Su Y.","year":"2021","unstructured":"Su Y.; Zhang B.; Sun R.; Liu W.; Zhu Q.; Zhang X.; Wang R.; Chen C.; PLGA-based biodegradable microspheres in drug delivery: Recent advances in research and application. Drug Deliv  2021,28(1),1397-1418","journal-title":"Drug Deliv"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"129392","DOI":"10.1016\/j.cej.2021.129392","volume":"418","author":"Zheng B.","year":"2021","unstructured":"Zheng B.; Peng W.; Guo M.; Huang M.; Gu Y.; Wang T.; Ni G.; Ming D.; Inhalable nanovaccine with biomimetic coronavirus structure to trigger mucosal immunity of respiratory tract against COVID-19. Chem Eng J  2021,418,129392","journal-title":"Chem Eng J"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/j.1747-0285.2008.00746.x","volume":"73","author":"Pimentel T.A.P.F.","year":"2009","unstructured":"Pimentel T.A.P.F.; Yan Z.; Jeffers S.A.; Holmes K.V.; Hodges R.S.; Burkhard P.; Peptide nanoparticles as novel immunogens: Design and analysis of a prototypic severe acute respiratory syndrome vaccine. Chem Biol Drug Des  2009,73(1),53-61","journal-title":"Chem Biol Drug Des"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"109","DOI":"10.4155\/tde.10.16","volume":"1","author":"Paudel K.S.","year":"2010","unstructured":"Paudel K.S.; Milewski M.; Swadley C.L.; Brogden N.K.; Ghosh P.; Stinchcomb A.L.; Challenges and opportunities in dermal\/transdermal delivery. Ther Deliv  2010,1(1),109-131","journal-title":"Ther Deliv"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mser.2016.03.001","volume":"104","author":"Larra\u00f1eta E.","year":"2016","unstructured":"Larra\u00f1eta E.; Lutton R.E.M.; Woolfson A.D.; Donnelly R.F.; Microneedle arrays as transdermal and intradermal drug delivery systems: Materials science, manufacture and commercial development. Mater Sci Eng Rep  2016,104,1-32","journal-title":"Mater Sci Eng Rep"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.jconrel.2009.06.029","volume":"139","author":"Chen X.","year":"2009","unstructured":"Chen X.; Prow T.W.; Crichton M.L.; Jenkins D.W.K.; Roberts M.S.; Frazer I.H.; Fernando G.J.P.; Kendall M.A.F.; Dry-coated microprojection array patches for targeted delivery of immunotherapeutics to the skin. J Control Release  2009,139(3),212-220","journal-title":"J Control Release"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"865001","DOI":"10.3389\/fmicb.2022.865001","volume":"13","author":"Li X.G.","year":"2022","unstructured":"Li X.G.; Chen J.; Wang W.; Lin F.; Li L.; Liang J.J.; Deng Z.H.; Zhang B.Y.; Jia Y.; Su Y.B.; Kang Y.F.; Du J.; Liu Y.Q.; Xu J.; Lu Q.B.; Oseltamivir treatment for influenza during the flu season of 2018\u20132019: A longitudinal study. Front Microbiol  2022,13,865001","journal-title":"Front Microbiol"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"2100996","DOI":"10.1002\/adhm.202100996","volume":"10","author":"Zhao L.","year":"2021","unstructured":"Zhao L.; Zhang C.; Abu-Ershaid J.M.; Li M.; Li Y.; Naser Y.; Dai X.; Abbate M.T.A.; Donnelly R.F.; Smart responsive microarray patches for transdermal drug delivery and biological monitoring. Adv Healthc Mater  2021,10(20),2100996","journal-title":"Adv Healthc Mater"}],"container-title":["Current Pharmaceutical Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113892010326373241012061547","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/235530\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113892010326373241012061547","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T05:50:54Z","timestamp":1764568254000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/235530\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":92,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0113892010326373241012061547","relation":{},"ISSN":["1389-2010"],"issn-type":[{"value":"1389-2010","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2024-06-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-30","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}